logo
  • Home
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls / Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact
    • Social Media Community Guidelines

All SEC Filings

Navigation Toggle Navigation
  • Overview
  • News / Events
  • Shareholder Calls / Presentations
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
Filter Filings:
Date Form Description Docs XBRL Pages
11/13/24 SC 13G/A Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions HTML PDF 4
09/17/24 NT 10-Q Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB HTML PDF 2
09/17/24 10-Q Quarterly report pursuant to Section 13 or 15(d)
Related Documents
EX-31.1
EX-31.2
EX-32.1
EX-32.2
HTML PDF XBRL Viewer XLS XBRL Files 26
08/13/24 10-K Annual report pursuant to Section 13 and 15(d)
Related Documents
EX-4.2
EX-19.1
EX-21.1
EX-23.1
EX-23.2
EX-31.1
EX-31.2
EX-32.1
EX-32.2
EX-97.1
HTML PDF XBRL Viewer XLS XBRL Files 101
07/29/24 NT 10-K Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10-KT HTML PDF 2
07/17/24 4 Statement of changes in beneficial ownership of securities HTML PDF 1
07/17/24 4 Statement of changes in beneficial ownership of securities HTML PDF 1
07/17/24 4 Statement of changes in beneficial ownership of securities HTML PDF 1
07/17/24 4 Statement of changes in beneficial ownership of securities HTML PDF 1
05/30/24 SC 13D Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities HTML PDF 4
RSS
  • << Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...43
  • Next >>

Contact Us

PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway, Suite 500
Las Vegas, Nevada 89169
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com

Latest News

  • PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease May 21, 2024
  • PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. November 15, 2023